Vol 5 Issue 5

CELL AND GENE THERAPY INSIGHTS

May 2019 Issue

Vol 5 Issue 5

Download PDF

Featuring

Issue Spotlight: Cellular Immuno-Oncology 4.0
Other articles
Webinars

SPOTLIGHT

Cellular Immuno-Oncology 4.0
Mark Lowdell
Guest Editor:
Mark Lowdell, Professor of Cell & Tissue Therapy at University College London

Editorial

The immunosuppressive tumor microenvironment: more than just immune checkpoints

The immunosuppressive tumor microenvironment: more than just immune checkpoints

Mark Lowdell
4 July 2019
Read

Expert Insight

CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

Claudia Rössig
13 August 2019
Read
Natural killer cells may be scaled and engineered as a next generation, off-the-shelf cell therapy for cancer

Natural killer cells may be scaled and engineered as a next generation, off-the-shelf cell therapy for cancer

James B Trager
4 July 2019
Read
Current state of genetically engineered macrophages for anti-cancer therapy

Current state of genetically engineered macrophages for anti-cancer therapy

N AP Lieberman, S Kreuser, C Lopez et al.
4 July 2019
Read
Gene editing platforms for T-cell immunotherapy

Gene editing platforms for T-cell immunotherapy

Xiuyan Wang, Isabelle Rivière
4 July 2019
Read
Genetically modified natural killer cells: an ‘off-the-shelf’ immunotherapy for cancer

Genetically modified natural killer cells: an ‘off-the-shelf’ immunotherapy for cancer

Subhashis Sarkar, Cillian O’Ceallaigh, Michael O’Dwyer
4 July 2019
Read

Innovator Insight

Novel equipment and process changes: implications for your manufacturing strategy

Novel equipment and process changes: implications for your manufacturing strategy

Nina G Bauer
15 July 2019
Read

Expert Roundtable Video

Expert Roundtable on immuno-oncology manufacturing: progress towards streamlined commercialization

Expert Roundtable on immuno-oncology manufacturing: progress towards streamlined commercialization

A Davies, Ø Åmellem, K Niss et al.
28 July 2019
Watch

Expert Roundtable

Immuno-oncology manufacturing: progress towards streamlined commercialization

Immuno-oncology manufacturing: progress towards streamlined commercialization

A Davies, Ø Åmellem, K Niss et al.
12 August 2019
Read
Gaining critical characterization insights for development of CAR-T therapies for solid tumors

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

S Kassim, J Krishnamurthy, T Laskowski et al.
28 July 2019
Read

Perspective

How biomarkers can be used to optimize the clinical development of dendritic cell vaccines in immuno-oncology

How biomarkers can be used to optimize the clinical development of dendritic cell vaccines in immuno-oncology

Marcelo Bravo
4 July 2019
Read
The advantage of allogenicity when using Inflammatory dendritic cells as antitumor immune primers

The advantage of allogenicity when using Inflammatory dendritic cells as antitumor immune primers

S Longhurst, J Kovacka, E Heimann et al.
4 July 2019
Read
Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?

Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?

P J Fairchild, T Davies, C Horton et al.
1 July 2019
Read

Interview

Invariant NKT cells: progress in transitioning to the clinic

Invariant NKT cells: progress in transitioning to the clinic

Anastasios Karadimitris
29 July 2019
Read
Building robustness and scalability into the immuno-oncology supply chain

Building robustness and scalability into the immuno-oncology supply chain

Lindsey Clarke
22 July 2019
Read
Leading the charge: driving allogeneic CAR T cell immunotherapy towards clinical and commercial success

Leading the charge: driving allogeneic CAR T cell immunotherapy towards clinical and commercial success

David Chang
4 July 2019
Read
Taking on solid tumors with genetically engineered macrophages

Taking on solid tumors with genetically engineered macrophages

Steven Kelly, Michael Klichinsky
4 July 2019
Read
γδT cells and the future of drug resistant immunotherapy

γδT cells and the future of drug resistant immunotherapy

Lawrence Lamb
4 July 2019
Read
The promise of tumor-targeted gene-based delivery of immune-activating cytokines

The promise of tumor-targeted gene-based delivery of immune-activating cytokines

Luigi Naldini
4 July 2019
Read

Journal articles

Interview

Designing your facilities and processes with commercialization in mind

Designing your facilities and processes with commercialization in mind

Peter Walters, Kim Nelson
24 June 2019
Read

Conference Insight

ISCT 2019 Commercialization Signature Series

ISCT 2019 Commercialization Signature Series

Miguel Forte
1 July 2019
Read

Commercial Insights

Cell & Gene Therapy Commercial Insight – May 2019

Cell & Gene Therapy Commercial Insight – May 2019

Mark Curtis, Richard Philipson
8 July 2019
Read
Cell & Gene Therapy Commercial Insight – April 2019

Cell & Gene Therapy Commercial Insight – April 2019

Mark Curtis, Richard Philipson
27 May 2019
Read

Webinars